No near-term catalyst — the Phase 2 trial is over two years from data. Monitor for any financing needs to support the trial, as the company is pre-revenue with a $54M market cap. The board appointment is a positive governance signal but not a trading event.
Price Chart
Executive Summary
Eloxx Pharmaceuticals appointed Geno J. Germano to its board (expanding from five to six directors) and announced the finalized Phase 2 trial design for exaluren in ADPKD, with first dosing expected in Q3 2027 and topline data in H1 2029. The board addition brings deep pharma experience, but the trial is years away from data and provides no near-term catalyst.
Key Facts
- Board expanded from 5 to 6 directors; Geno J. Germano appointed as independent director.
- Germano received an option to purchase 13,587 shares at $12.50 per share, vesting over 24 months.
- Phase 2 trial EXPRESS for exaluren in ADPKD: ~60 patients, 1:1 randomization vs placebo, 52-week treatment.
- Primary endpoint: annualized rate of change in height-adjusted total kidney volume.
- First patient dosing expected Q3 2027; topline data expected H1 2029.
- Exaluren has orphan drug designations for ADPKD in the US and Europe.
Financial Impact
No financial figures reported; option grant of 13,587 shares at $12.50 is immaterial relative to market cap.
Risk Factors
- Phase 2 trial may fail to meet primary endpoint; no prior clinical data for exaluren in ADPKD.
- Long timeline to data (H1 2029) with no revenue; cash runway risk is material for a $54M market cap biotech.
- Option grant at $12.50 per share may signal management's view of fair value, but current market price is unknown.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-428116 |
| Document: 0001193125-26-428116-index-headers.html | 0001193125-26-428116 |
| Document: 0001193125-26-428116-index.html | 0001193125-26-428116 |
| Document: 0001193125-26-428116.txt | 0001193125-26-428116 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $13.12 | awaiting T+20 | — | $13.34 (+1.68%) |
Sep 21, 2026 5w ago | EFFECT | $17.19 $12.50 | ▼ −27.28% | ▼ −26.38% | $13.34 (−22.40%) |
Sep 11, 2026 6w ago | S-1 | $16.30 | awaiting T+20 | — | $13.34 (−18.16%) |
Jun 9, 2026 20w ago | EFFECT | $11.01 $10.95 | ▼ −0.55% | ▼ −1.99% | $13.34 (+21.16%) |
Jun 4, 2026 20w ago | S-1/A | $6.20 | awaiting T+20 | — | $13.34 (+115.16%) |
Jun 1, 2026 21w ago | S-1/A | $1.51 | awaiting T+20 | — | $13.34 (+783.44%) |
Jun 1, 2026 21w ago | 8-K | $4.07 $13.88 | ▲ +241.03% | ▲ +242.33% | $13.34 (+227.76%) |
May 7, 2026 24w ago | S-1 | $1.43 | awaiting T+20 | — | $13.34 (+832.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers